GNH India

What GNH India does

GNH India Pharmaceuticals Limited, founded in 2003 and headquartered in Mumbai, is a privately held B2B pharmaceutical distributor specializing in the cross-border supply of specialty, orphan, unlicensed, and hard-to-access medicines. The company serves institutional clients including hospitals, government health bodies, contract research organizations (CROs), pharmaceutical manufacturers, and licensed medical practitioners across more than 180 countries. GNH India's core proposition is bridging access gaps in pharmaceutical supply chains for rare diseases, clinical trials, and public health programs where commercial channels are inadequate or unavailable.

The company operates through seven integrated service lines: Named Patient Supply (regulated access to unapproved medicines for individual patients), Clinical Trials Supply (end-to-end logistics for investigational products and comparators), Orphan Drug Supply (rare disease medicines via EMA/FDA/PMDA-designated manufacturers), Parallel Import (cross-border compliant sourcing of licensed medicines), Pharmaceutical Contract Manufacturing (coordination with WHO-GMP, US FDA, and UK MHRA certified facilities), Government Supply Services (public tender participation), and Dossiers & Stability Studies (CTD/eCTD documentation, ICH Q1A(R2) stability programs). Underlying technology centers on GDP-compliant cold-chain logistics with validated packaging, in-transit temperature data loggers, and GMP-compliant stability chambers operating from -20°C to +40°C. The product catalogue spans 235,385+ lines across branded generics, biologics, oncology drugs, antibiotics, insulins, and diagnostic agents.

GNH India monetizes through quote-based pricing on pharmaceutical distribution (mark-up on sourced products) and professional/managed service fees for clinical trial coordination, regulatory documentation, contract manufacturing facilitation, and parallel import logistics. The company reports 12+ million dose cycles delivered, 100+ tons shipped, 500+ clinical trials supported across 40+ countries, and a 99.8% on-time delivery rate for clinical trial supplies. Operations are certified under WHO-GSDP, ISO 9001:2015, and SGS GDP, with regulatory memberships in Pharmexcil and FIEO. The company maintains a US subsidiary (GNH Pharmaceuticals USA LLC in Charlotte, NC) alongside the Mumbai headquarters, and is led by founder-CEO Dr. Piyush Gupta and Dr. Jessica Gupta (QA Director). No external funding rounds, acquisitions, or institutional investors are disclosed.

Name

GNH India

Legal name

GNH India Pharmaceuticals Limited

Website

https://gnhindia.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

GNH India is a Mumbai-based B2B pharmaceutical distributor founded in 2003 that supplies orphan, unlicensed, and specialty medicines to hospitals, governments, CROs, and physicians across 180+ countries through validated cold-chain logistics and seven integrated service lines.

Ownership category

akta.pro rank

Product category

Pharmaceutical Distribution

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Refrigerated Warehousing and Storage (493120)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Public Warehousing & Storage (4220)

akta.pro primary industry

Pharmaceutical Cold Chain & Temperature-Controlled Distribution (CRAOAHAH)

akta.pro secondary industries

GxP Warehousing, Storage & Distribution (ambient + controlled) (HLAGAMAH), Pharmaceuticals & Life Sciences Forwarding (GxP/GDP) (TLACAJAB), Clinical Trials & Investigational Product (IP) Cold Chain Logistics (TLAIAIAC), Pharmaceutical & Biopharma Cold Chain Logistics (2–8°C, CRT, GDP) (TLAIAIAA), Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor) (HLAIAJAF)

Keywords

• Pharmaceutical distribution
• Orphan drug supply
• Named patient supply
• Clinical trial supply
• Pharmaceutical cold chain

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Distribution & Wholesaling: Full-line pharmaceutical wholesaler supplying branded, generic, orphan, and unlicensed medicines to hospitals, healthcare institutions, and licensed medical practitioners globally. Revenue generated through product sales with mark-up on sourced pharmaceutical products.
2. Named Patient Supply Services: Sourcing and supplying unapproved, unavailable, or critical medicines to patients through Named Patient Programs. Fees charged for regulatory coordination, sourcing, and logistics management for individual patient cases.
3. Clinical Trial Supply Services: End-to-end clinical trial supply chain management including sourcing of investigational products, comparator drugs, placebos, cold-chain logistics, and global distribution to research sites. Revenue from supply fees and logistics coordination.
4. Contract Manufacturing Coordination: Connecting pharmaceutical companies with certified manufacturing partners (WHO-GMP, US FDA, UK MHRA certified facilities) for branded generics, vaccines, and neutral label products. Revenue from coordination and regulatory support services.
5. Government Supply Services: Participation in public tenders and direct supply of critical medicines to government hospitals, health departments, and non-profit programs. Revenue from tender contracts and institutional supply agreements.
6. Dossiers & Stability Studies: Preparation of CTD/eCTD dossiers, conduct of stability studies, and support for BA/BE studies to meet regulatory authority requirements. Revenue from regulatory consulting and documentation services.
7. Parallel Import Services: Cross-border supply of licensed medicines from approved markets into markets where medicines are unavailable, in shortage, or pending registration. Revenue from arbitrage and logistics coordination.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels4 records

Core offering

GNH India is a B2B pharmaceutical distributor that sources and supplies over 650,000+ branded, generic, orphan, and unlicensed medicines to hospitals, government bodies, CROs, and licensed medical practitioners across 180+ countries. The company specializes in Named Patient Supply programs, clinical trial supply chain management, parallel import, contract manufacturing coordination, government tender supply, and regulatory documentation (CTD/eCTD dossiers and ICH stability studies), backed by validated GDP-compliant cold-chain logistics spanning -80°C to +25°C.

Product overview

GNH India is a WHO-GSDP certified global pharmaceutical distributor founded in 2003, offering a comprehensive portfolio of pharmaceutical products and services across 180+ countries. The company operates through seven core service lines: Named Patient Supply (access to unapproved/unlicensed medicines for individual patients), Clinical Trials Supply (end-to-end supply chain for pharmaceutical research), Orphan Drug Supply (rare disease medicines), Parallel Import (cross-border compliant medicine sourcing), Pharmaceutical Contract Manufacturing (third-party manufacturing coordination), Government Supply Services (public sector procurement), and Dossiers & Stability Studies (regulatory documentation). The product portfolio includes over 650,000+ pharmaceutical product lines spanning branded generics, specialty medicines, biologics, diagnostic agents (such as Indocyanine Green), oncology drugs (Carboplatin, Fluorouracil), antibiotics (Rifampicin), hormones (Conjugated Estrogens), insulins, and weight management medications. The company maintains ISO 9001:2015 certification and serves hospitals, government bodies, CROs, and licensed healthcare institutions.

Differentiator

Problem solved

Functional benefit

Products and services

• Named Patient Supply A regulated pharmaceutical program enabling patients with rare and life-threatening conditions to access medications not yet approved, available, or registered in their country through compliant Named Patient Programs, compassionate use, and early access frameworks. Physician-initiated requests are processed by licensed pharmacists with secure delivery to hospital pharmacies or authorized healthcare facilities.
• Clinical Trials Supply End-to-end clinical trial supply chain management including investigational product sourcing, comparator drugs, rescue medications, co-medications, GMP warehousing, cold-chain logistics, labeling, global distribution, and regulatory compliance for Phase I-IV studies. Supports 500+ clinical trials with 99.8% on-time delivery across 40+ countries.
• Orphan Drug Supply Specialized supply of orphan drugs and rare disease medicines to patients in 180+ countries through Named Patient Programs, parallel import, and compassionate use frameworks, leveraging relationships with manufacturers holding EMA, FDA, and PMDA orphan drug designations.
• Parallel Import Compliant cross-border supply of fully licensed medicines imported into markets where they may not be locally registered, experiencing shortages, or commercially unavailable, serving licensed pharmaceutical companies, hospital procurement teams, and government health bodies.
• Pharmaceutical Contract Manufacturing Third-party pharmaceutical manufacturing coordination through WHO-GMP, US FDA, and UK MHRA approved facilities for branded generics, vaccines, and neutral label products across multiple therapeutic areas and dosage forms.
• Government Supply Services Public sector pharmaceutical procurement and distribution through tender participation, regulatory documentation management, and cold-chain logistics supplying essential medicines to government hospitals, health departments, and non-profit programs.
• Dossiers & Stability Studies Regulatory documentation preparation services including CTD/eCTD dossier compilation, ICH Q1A(R2) compliant stability studies conducted in GMP chambers operating from -20°C to +40°C and 25-75% RH, and support for BA/BE studies to meet regulatory authority requirements in international markets.

Quantifiable outcome

• 99.8% on-time delivery rate for clinical trial supplies across 40+ countries
• +4 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core.

• Pharmaexcil (Pharmaceuticals Export Promotion Council of India)coreOthersGNH India is a registered member of Pharmaexcil, the Pharmaceuticals Export Promotion Council of India. Membership provides trade promotion support, market intelligence, and reflects commitment to ethical pharmaceutical exports and global trade compliance.
• FIEO (Federation of Indian Export Organisations)coreOthersGNH India is a member of FIEO, the Federation of Indian Export Organisations. Membership supports Indian export trade compliance and provides access to export promotion resources and networks.
• WHO-GMP, US FDA, and UK MHRA Certified Manufacturing FacilitiescoreStrategic or Co-development PartnerGNH India maintains a network of certified manufacturing partners with WHO-GMP, US FDA, and UK MHRA certifications for pharmaceutical contract manufacturing services including branded generics, vaccines, and neutral label products.
• Global Orphan Drug Manufacturers (EMA/FDA/PMDA Designated)coreStrategic or Co-development PartnerGNH India sources orphan drugs directly from manufacturers holding orphan designation from EMA, FDA, or PMDA, or from their authorized distributors. These partnerships enable supply of rare disease medicines to 180+ countries through Named Patient Programs and compassionate use pathways.

Scale indicators10 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Cardinal Health: Large US-based pharmaceutical distributor with global specialty distribution and biopharma services. Operates in adjacent pharma distribution segments but at a significantly different scale and primarily US-centric footprint.
• McKesson: One of the world's largest pharmaceutical wholesalers and distributors with global specialty pharma, cold-chain, and clinical trial logistics services. Competitor in the broader pharma distribution market; overlaps with GNH India on specialty drug distribution and clinical supply.
• Cencora (AmerisourceBergen): Global pharmaceutical distribution and solutions company with specialty distribution, clinical trial supply, and animal health segments. Indirectly comparable to GNH India through specialty and clinical trial distribution capabilities at much larger scale.
• Zuellig Pharma: Large Asia-Pacific headquartered pharmaceutical distribution and healthcare services group with extensive cold-chain logistics and specialty pharma capabilities. Overlapping with GNH India on pharma distribution and cold-chain but at significantly larger scale and broader portfolio.

Direct peers

• World Courier (Cencora): Specialty courier and clinical trial logistics provider offering temperature-controlled pharmaceutical transport and clinical supply chain services. Directly comparable to GNH India on cold-chain clinical trial logistics and temperature-controlled pharma transport.
• BAP Pharma: UK-headquartered unlicensed and named-patient medicines supplier focused on oncology and rare disease therapies. Comparable to GNH India on cross-border named patient supply, parallel import, and orphan drug sourcing.
• Clinigen Group: UK-based specialty pharma services company providing clinical trial supply, unlicensed/compassionate use medicines, and named patient supply globally. Most directly comparable to GNH India on named patient programs, clinical trial supply, and orphan drug access.
• Tanner Pharma Group: US-based specialty pharma services firm focused on named patient supply, comparator sourcing, and international clinical trial support. Directly comparable on cross-border named patient access, comparator drug sourcing, and clinical supply services.
• Eurocept International: Dutch specialty pharmaceutical company providing named patient access and unlicensed medicine distribution across Europe and emerging markets. Closely matches GNH India's named patient / unlicensed medicines franchise and regulatory specialization.

Regional players

• Medipal Holdings: Japan's largest pharmaceutical wholesaler with distribution across Asia and cold-chain pharma capabilities. Comparable on pharmaceutical distribution and cold-chain logistics but primarily focused on Japan/Asia rather than global named-patient supply.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/GNH-India-Pharma-100083581940378
• LinkedInlinkedin.com/company/gnh-india-pharmaceuticals-limited

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GNH India